OncoMatch/Clinical Trials/NCT06749691
Liposomal Irinotecan and Apatinib in ES-SCLC
Is NCT06749691 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Liposomal Irinotecan and Apatinib for small cell lung cancer extensive stage.
Treatment: Liposomal Irinotecan and Apatinib — The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
at least one measurable lesion (according to RECIST V 1.1)
Demographics
Prior therapy
Must have received: any systemic therapy — first-line or second-line
For patients who have failed first-line or second-line treatment.
Cannot have received: VEGF or VEGFR-targeted therapy (ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, sorafenib)
Have received any systemic treatment targeting VEGF or VEGFR in the past, such as treatment with anti angiogenic drugs such as ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, sorafenib.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06749691 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior VEGF or VEGFR-targeted therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages